Pulmozyme: clinical and economic impacts
Perras C, Otten N
Record ID 31999008084
To summarise the available evidence relating to the cost-effectiveness of pulmozyme in the treatment of cystic fibrosis (CF).
Authors' recomendations: This study found that the most important factors affecting costs are the per diem rates and the number of hospitalisations. Considering the savings accrued from decreased hospitalisation, DNase is still a more costly alternative than no DNase.
Authors' methods: Cost study
Project Status: Completed
URL for project: https://www.ccohta.ca/pubs/overpulmozyme-3.html
Year Published: 1996
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Costs and Cost Analysis
- Cystic Fibrosis
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
Copyright: Canadian Coordinating Office for Health Technology Assessment
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.